Drug Trial Radar · NCT06021678
Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Feb 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
415
Planned (sponsor's estimate)
Start
Nov 12, 2021
Primary completion
Oct 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Guangzhou Excelmab Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, single-arm, open, dose-escalation Phase I/II clinical trial, consisting of a dose-escalation phase (accelerated titration phase, 3+3 design) and a dose expansion phase.
Conditions
- CD20-positive Non-Hodgkin Lymphoma
Interventions
EX103 injectionDrug
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLTs) [dose escalation (Cycle 0 and Cycle 1)]Time frame: During the DLT evaluation period (28 days from Cycle1 Day1 at the dose escalation stage).
- Safety endpoints:incidence and severity of adverse events (AE), laboratory tests, etc.Time frame: From first dose until the end of the safety follow-up period [within 28 ± 7 days after the last study treatment or before the start of other anti-tumor treatments (whichever occurs earlier)].
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Affiliated to Zhengzhou University, Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Qilu Hospital, Cheeloo College of Medicine, Shandong University
Jinan, Shandong, China · Recruiting
Shanghai Sixth People's Hospital, Shanghai Jiaotong University school of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.